Takeda Pharmaceutical Company Ltd. Company
Takeda Pharmaceutical Company Limited operates as a research-based pharmaceutical company in Japan.
The Japanese drugmaker said March 4 it plans to test hyperimmune globulins for people who are at high risk for infection. As part of its research, which will be performed in Georgia, Takeda said it would need access to plasma from people who have recovered from COVID-19 or those who have received a vaccine if one is developed. Dr. Rajeev Venkayya, president of Takeda’s vaccine business, is the co-lead of the company’s COVID-19 response team. Like J&J, Takeda plans to examine whether other therapies, both experimental or with regulatory approval, may have treatment potential. In April, Takeda and CSL Behring CSLLY, -4.68% said they formed an alliance to develop a plasma-derived treatment for COVID19. Biotest AG and Octapharma also joined the alliance.
The Japanese drugmaker said March 4 it plans to test hyperimmune globulins for people who are at high risk for infection. As part of its research, which will be performed in Georgia, Takeda said it would need access to plasma from people who have recovered from COVID-19 or those who have received a vaccine if one is developed. Dr. Rajeev Venkayya, president of Takeda’s vaccine business, is the co-lead of the company’s COVID-19 response team. Like J&J, Takeda plans to examine whether other therapies, both experimental or with regulatory approval, may have treatment potential. In April, Takeda and CSL Behring CSLLY, -4.68% said they formed an alliance to develop a plasma-derived treatment for COVID19. Biotest AG and Octapharma also joined the alliance.
Technology:
COVID
Industry:
Treatments
Headquarters:
Japan
Founded Date:
N/A
Employees Number:
N/A
Funding Status:
N/A
Register and Claim Ownership